作者投稿
专家审稿
编辑办公
邮件订阅
RSS
Current status and controversies in the diagnosis and treatment of gastric neuroendocrine tumors
-
摘要:
随着胃神经内分泌肿瘤（ G-NENs） 发病率的不断提高， 临床医生对该病的认识也在不断加深， 但有关 G-NENs 的诊断及治疗目前仍存在较多争议。 因此， 本文就 G-NENs 的诊治现状作一综述，并对现存争议进行讨论， 旨在为临床医师的规范化诊治提供参考。
Abstract:With the increasing morbidity of gastric neuroendocrine neoplasms (G-NENs), the understanding of clinicians about G-NENs is also deepening. However, there are still have many controversies regarding the diagnosis and treatment of GNENs. Therefore, this article reviews the current status of diagnosis and treatment of G-NENs, and discusses the existing controversies, aiming to provide reference for clinicians in standardized diagnosis and treatment.
-
Key words:
- gastric neuroendocrine neoplasms /
- diagnosis /
- treatment /
- controversy
-
[1] Liu XM,Tuo BG.[Endoscopic diagnosis and treatment of gastrointestinal neuroendocrineneoplasms][J].Zhonghua Wei Chang Wai Ke Za Zhi,2021,24(10):854-860. [2] Cives M,Strosberg JR.Gastroenteropancreatic Neuroendocrine Tumors[J].CA Cancer J Clin,2018,68(6):471-487. [3] Exarchou K,Stephens NA,Moore AR, et al.New Developments in Gastric NeuroendocrineNeoplasms[J].Curr Oncol Rep,2022,24(1):77-88. [4] Roberto GA,Rodrigues CMB,Peixoto RD, et al.Gastric neuroendocrine tumor: A practical literaturereview[J].World J Gastrointest Oncol,2020,12(8):850-856. [5] 中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组.胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州)[J].中华消化杂志,2021,41(02):76-87. [6] 谭煌英.胃神经内分泌肿瘤临床分型的共识和争议[J].中华胃肠外科杂志,2017,20(09):977-981. [7] Delle Fave G,Kwekkeboom DJ,Van Cutsem E, et al.ENETS Consensus Guidelines for the management ofpatients with gastroduodenal neoplasms[J].Neuroendocrinology,2012,95(2):74-87. [8] Delle Fave G,O'Toole D,Sundin A, et al.ENETS Consensus Guidelines Update for GastroduodenalNeuroendocrine Neoplasms[J].Neuroendocrinology,2016,103(2):119-124. [9] 徐建明,梁后杰,秦叔逵,等.中国胃肠胰神经内分泌肿瘤专家共识(2016年版)[J].临床肿瘤学杂志,2016,21(10):927-946. [10] 李洁,张盼盼.胃神经内分泌肿瘤的诊治现状[J].中国医师进修杂志,2017,40(07):656-660. [11] Domori K,Nishikura K,Ajioka Y, et al.Mucin phenotype expression of gastric neuroendocrine neoplasms:analysis of histopathology and carcinogenesis[J].Gastric Cancer,2014,17(2):263-272. [12] Pak LM,Yang T,Wang J.Further Classification for Node-Positive Gastric Neuroendocrine Neoplasms[J].JGastrointest Surg,2019,23(4):720-729. [13] Gluckman CR,Metz DC.Gastric Neuroendocrine Tumors (Carcinoids)[J].Curr GastroenterolRep,2019,21(4):13. [14] Sansone A,Lauretta R,Vottari S, et al.Specific and Non-Specific Biomarkers in NeuroendocrineGastroenteropancreatic Tumors[J].Cancers (Basel),2019,11(8):1113. [15] Filosso PL,Kidd M,Roffinella M, et al.The utility of blood neuroendocrine gene transcript measurement inthe diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection anddisease progression[J].Eur J Cardiothorac Surg,2018,53(3):631-639. [16] Modlin IM,Kidd M,Bodei L, et al.The clinical utility of a novel blood-based multi-transcriptome assay forthe diagnosis of neuroendocrine tumors of the gastrointestinal tract[J].Am J Gastroenterol,2015,110(8):1223-1232. [17] Malczewska A,Procner A,Walter A, et al.The NETest liquid biopsy is diagnostic for gastric neuroendocrinetumors: observations on the blood-based identification of microscopic and macroscopic residualdiseaseOK[J].BMC Gastroenterol,2020,20(1):235. [18] van Treijen MJC,Korse CM,van Leeuwaarde RS, et al.Blood Transcript Profiling for the Detection ofNeuroendocrine Tumors: Results of a Large Independent Validation Study[J].Front Endocrinol(Lausanne),2018,9:740. [19] Zilli A,Arcidiacono PG,Conte D, et al.Clinical impact of endoscopic ultrasonography on the management ofneuroendocrine tumors: lights and shadows[J].Dig Liver Dis,2018,50(1):6-14. [20] Kos-Kudła B,Blicharz-Dorniak J,Strzelczyk J, et al.Diagnostic and therapeutic guidelines for gastro-enteropancreatic neuroendocrine neoplasms (recommended by the Polish Network of NeuroendocrineTumours)[J].Endokrynol Pol,2017,68(2):79-110. [21] Yu R,Wachsman A.Imaging of Neuroendocrine Tumors: Indications, Interpretations, Limits, andPitfalls[J].Endocrinol Metab Clin North Am,2017,46(3):795-814. [22] Dromain C,de Baere T,Lumbroso J, et al.Detection of liver metastases from endocrine tumors: a prospectivecomparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonanceimaging[J].J Clin Oncol,2005,23(1):70-78. [23] Barat M,Soyer P,Al Sharhan F, et al.Magnetic Resonance Imaging May Be Able to Identify the Origin ofNeuroendocrine Tumor Liver Metastases[J].Neuroendocrinology,2021,111(11):1099-1110. [24] Inaba Y,Hijioka S,Iwama I, et al.Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosisof Neuroendocrine Neoplasms[J].Asia Ocean J Nucl Med Biol,2022,10(1):1-13. [25] Yu J,Li N,Li J, et al.The Correlation Between [(68)Ga]DOTATATE PET/CT and Cell Proliferation in PatientsWith GEP-NENs[J].Mol Imaging Biol,2019,21(5):984-990. [26] Carideo L,Prosperi D,Panzuto F, et al.Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and[(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review[J].J Clin Med,2019,8(7):1032. [27] Delpassand ES,Ranganathan D,Wagh N, et al.(64)Cu-DOTATATE PET/CT for Imaging Patients with Knownor Suspected Somatostatin Receptor-Positive Neuroendocrine Tumors: Results of the First U.S. Prospective,Reader-Masked Clinical Trial[J].J Nucl Med,2020,61(6):890-896. [28] Johnbeck CB,Knigge U,Loft A, et al.Head-to-Head Comparison of (64)Cu-DOTATATE and (68)Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors[J].J NuclMed,2017,58(3):451-457. [29] Nagtegaal ID,Odze RD,Klimstra D, et al.The 2019 WHO classification of tumours of the digestivesystem[J].Histopathology,2020,76(2):182-188. [30] Zheng X,Guo K,Wasan HS, et al.A population-based study: how to identify high-risk T1 gastric cancerpatients?[J].Am J Cancer Res,2021,11(4):1463-1479. [31] Shah MH,Goldner WS,Benson AB, et al.Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCNClinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2021,19(7):839-868. [32] Daskalakis K,Tsoli M,Karapanagioti A, et al.Recurrence and metastatic potential in Type 1 gastricneuroendocrine neoplasms[J].Clin Endocrinol (Oxf),2019,91(4):534-543. [33] 王玮,周志伟.胃神经内分泌肿瘤的外科治疗[J].中华胃肠外科杂志,2021,24(10):849-853. [34] Fukui Y,Kato Y,Okazaki Y, et al.[A 3mm Gastric Neuroendocrine Tumor That Metastasized to a LymphNode][J].Gan To Kagaku Ryoho,2018,45(13):1839-1841. [35] Hirasawa T,Yamamoto N,Sano T.Is endoscopic resection appropriate for type 3 gastric neuroendocrinetumors? Retrospective multicenter study[J].Dig Endosc,2021,33(3):408-417. [36] Chen J,Wang A,Ji K, et al.Comparison of overall survival of gastric neoplasms containing neuroendocrinecarcinoma components with gastric adenocarcinoma: a propensity score matching study[J].BMCCancer,2020,20(1):777. [37] Stueven AK,Kayser A,Wetz C, et al.Somatostatin Analogues in the Treatment of Neuroendocrine Tumors:Past, Present and Future[J].Int J Mol Sci,2019,20(12):3049. [38] Rinke A,Müller HH,Schade-Brittinger C, et al.Placebo-controlled, double-blind, prospective, randomizedstudy on the effect of octreotide LAR in the control of tumor growth in patients with metastaticneuroendocrine midgut tumors: a report from the PROMID Study Group[J].J Clin Oncol,2009,27(28):4656-4663. [39] Vinik AI,Wolin EM,Liyanage N, et al.EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACYAND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL[J].Endocr Pract,2016,22(9):1068-1080. [40] Gut P.Oncological management of advanced neuroendocrine tumours (Review)[J].Mol ClinOncol,2020,13(3):8. [41] Lee L,Ito T,Jensen RT.Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects,resistance, and factors affecting its place in the treatment sequence[J].Expert OpinPharmacother,2018,19(8):909-928. [42] Yao JC,Fazio N,Singh S, et al.Everolimus for the treatment of advanced, non-functional neuroendocrinetumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3study[J].Lancet,2016,387(10022):968-977. [43] Yao JC,Shah MH,Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors[J].N Engl JMed,2011,364(6):514-523. [44] Yao JC,Lombard-Bohas C,Baudin E, et al.Daily oral everolimus activity in patients with metastaticpancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial[J].J ClinOncol,2010,28(1):69-76. [45] Pavel ME,Hainsworth JD,Baudin E, et al.Everolimus plus octreotide long-acting repeatable for the treatmentof advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised,placebo-controlled, phase 3 study[J].Lancet,2011,378(9808):2005-2012. [46] Hasskarl J.Everolimus[J].Recent Results Cancer Res,2018,211:101-123. [47] 谈思源,陈平.胃肠胰神经内分泌瘤的药物治疗进展[J].中华临床医师杂志(电子版),2016,10(14):2158-2162. [48] Pobłocki J,Jasińska A,Syrenicz A, et al.The Neuroendocrine Neoplasms of the Digestive Tract: Diagnosis,Treatment and Nutrition[J].Nutrients,2020,12(5):1437. [49] Garcia J,Hurwitz HI,Sandler AB, et al.Bevacizumab (Avastin®) in cancer treatment: A review of 15 years ofclinical experience and future outlook[J].Cancer Treat Rev,2020,86:102017. [50] Boyce M,Moore AR,Sagatun L, et al.Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, caneradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis[J].Br J ClinPharmacol,2017,83(3):466-475. [51] Moore AR,Boyce M,Steele IA, et al.Netazepide, a gastrin receptor antagonist, normalises tumour biomarkersand causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients withchronic atrophic gastritis[J].PLoS One,2013,8(10):e76462. [52] Lania A,Ferraù F,Rubino M, et al.Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progressesand Future Approaches[J].Front Endocrinol (Lausanne),2021,12:651438. [53] Yamamoto M,Ozawa S,Koyanagi K, et al.Effectiveness of neoadjuvant chemotherapy with etoposide andcisplatin followed by surgery for esophageal neuroendocrine carcinoma: a case report[J].J ThoracDis,2018,10(6):E450-E455. [54] Ogawa H,Tanaka Y,Kitamura Y, et al.Efficacy of perioperative chemotherapy for pulmonary high-gradeneuroendocrine carcinomas: a propensity score matching analysis[J].J Thorac Dis,2019,11(4):1145-1154. [55] Tang H,Wang H,Xi S, et al.Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary largecell neuroendocrine carcinoma: a case report and literature review[J].Onco Targets Ther,2018,11:2557-2563. [56] Borga C,Businello G,Murgioni S, et al.Treatment personalization in gastrointestinal neuroendocrinetumors[J].Curr Treat Options Oncol,2021,22(4):29. [57] Strosberg J,El-Haddad G,Wolin E, et al.Phase 3 Trial of (177)Lu-Dotatate for Midgut NeuroendocrineTumors[J].N Engl J Med,2017,376(2):125-135. [58] Paganelli G,Sansovini M,Nicolini S, et al.(177)Lu-PRRT in advanced gastrointestinal neuroendocrine tumors:10-year follow-up of the IRST phase II prospective study[J].Eur J Nucl Med Mol Imaging,2021,48(1):152-160. [59] Yordanova A,Wicharz MM,Mayer K, et al.The Role of Adding Somatostatin Analogues to Peptide ReceptorRadionuclide Therapy as a Combination and Maintenance Therapy[J].Clin Cancer Res,2018,24(19):4672-4679. [60] Minczeles NS,Hofland J,de Herder WW, et al.Strategies Towards Improving Clinical Outcomes of PeptideReceptor Radionuclide Therapy[J].Curr Oncol Rep,2021,23(4):46. -
点击查看大图
计量
- 文章访问数: 46
- HTML全文浏览量: 2
- PDF下载量: 2
- 被引次数: 0
下载:
